Barclays raised the firm’s price target on Merck to $135 from $130 and keeps an Overweight rating on the shares. The analyst remains positively biased on U.S. biopharmaceuticals into most Q4 setups, “leaning into recent winners.” The firm recommends weighting towards names with strong prescription trends, supportive guides and potential upside to 2024 numbers. It prefers Eli Lilly (LLY), Merck (MRK), AbbVie (ABBV) Regeneron (REGN). Barclays says Bristol-Myers (BMY) and Pfizer (PFE) are the “most challenged.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Senate Health, Education, Labor & Pensions Committee holds an executive session
- Adagene falls after presenting interim results from study of ADG126
- Merck (NYSE:MRK): FDA Approves Expanded Use of Keytruda
- Merck: FDA approves Keytruda in combination with chemoradiotherapy
- Biotech Alert: Searches spiking for these stocks today